Search 

TusPark UK is a science and technology service corporation with an investment arm as a venture capital and private equity group fund. TusPark UK has invested £250M+ in Cambridge since 2018 (e.g. the landmark joint venture with the Trinity College to develop and operate TusPark Cambridge Science Park), and its investment portfolio spans in the era of life science/healthcare, digital technologies (big data, AI and IoT, etc.), new material, and environmental & new energy, with a unique model of "Incubation + Investment + M&As".

VISEN Pharmaceuticals, headquartered in Shanghai, China, is committed to the treatment of endocrine-related disease, introducing the world’s leading treatment methods and drugs into the China market, benefiting Chinese patients while unleashing product potential.

VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).

WEGO HOLDING COMPANY LIMITED (“WEGO”) was established in March 1988, and it principal business focus on medical devices and pharmaceuticals. In addition, WEGO develops some other business such as real estate and investment. WEGO has 8 industry groups and more than 30 subsidiaries. WEGO Holding's subsidiary ---SHANDONG WEIGAO GROUP MEDICAL POLYMER CO., LIMITED is listed in Hong Kong.

The main products of WEGO are infusion sets, syringes, blood transfusion equipments, heart stents, intracardiac consumables，IV catheters and special needles, blood purification equipments and consumables, orthopedic materials, operating room equipments and accessories, wound care products, minimally invasive instruments and equipments, ICU products and accessories, high-capacity injections and pharmaceuticals, renal products, biological diagnostic reagents, PVC & non-PVC materials and so on. WEGO now has products in more than 30 series, 400 categories and 60,000 specifications products, and has become one of the most reliable suppliers of medical system solutions in the world. At the same time, WEGO actively takes part in healthcare service and provides renal dialysis service.

In addition, under the branding strategy, the WEGO products are sold in more than 30 provinces and municipalities, which covered 81.3% of tertiary hospitals and 77.2% of blood banks in China, and also exported to over 70 countries and areas. WEGO is trying to become an international company, trying to achieve the vision of “To be one of the global elites; Pioneer in Asia; Most respectable medical device and medication enterprise”, and trying to make contributions to China's medical and healthcare industry.

Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.

Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992. Wondfo now has more than 3000 employees and a wide range of products for the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, widely sold to 140+ countries and regions.

A mainland based family fund， heavily investing healthcare and biotechs

WuXi Apptec provides a broad portfolio of R&D and manufacturing service that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.

Wuxi Biocity is a biopharmaceutical company mainly focusing on discovery, development, clinical trials and commercialization of "Best-in-Class" and "First-in-Class" original new drug of oncology and autoimmune diseases. Established in December 2017 in Wuxi, Biocity aims to benefit patients around the world as a pioneer pharmaceutical company in China with sustainable innovation ability and therapeutic products. With the noble mission of "Better Medicine for Better Life", our team always adhere to scientific evidence, while consider unfulfilled medical needs ahead of time, to achieve the goal of patient-centered, full-lifecycle disease management. Biocity's programs successfully entered into clinical stages within three years of efficient operation.



We are honored to have domestic and international academicians, well-known scientists, enterprise and policy specialists, clinical experts in particular, on our advisory board to guide Biocity's scientific, clinical, and strategic development. To reach our long-term goal of sustainable competitive advantages, we collaborate with the Wuxi government on multiple aspects to establish the "Biocity Innovation Institute for Translational Medicine". Thus we can further dig into the translational medical research from the discovery of disease mechanisms to the therapeutic applications of certain scientific achievements. Biocity Innovation Institute will strengthen our R&D ability and innovation capacity, therefore accelerate the popularization and enhancement of translational medicine in Wuxi, Jiangsu.



We have been recognized by many investment firms and intend to conduct an IPO in the very near future. With great efforts, we will bring safe and effective local innovative medicine at the best of times, to meet the increasing medical needs globally.